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ABSTRACT: Several studies have linked bacterial dysbiosis with elevated risk of colorectal
adenomas and cancer. However, the functional implications of gut dysbiosis remain
unclear. Gut bacteria contribute to nutrient metabolism and produce small molecules
termed the “metabolome”, which may contribute to the development of neoplasia in the
large bowel. We assessed the metabolome in normal rectal mucosal biopsies of 15 subjects
with colorectal adenomas and 15 nonadenoma controls by liquid chromatography and gas
chromatography time-of-flight mass spectrometry. Quantitative real-time PCR was used to
measure abundances of specific bacterial taxa. We identified a total of 274 metabolites.
Discriminant analysis suggested a separation of metabolomic profiles between adenoma
cases and nonadenoma controls. Twenty-three metabolites contributed to the separation,
notably an increase in adenoma cases of the inflammatory metabolite prostaglandin E2
and a decrease in antioxidant-related metabolites 5-oxoproline and diketogulonic acid.
Pathway analysis suggested that differential metabolites were significantly related to cancer,
inflammatory response, carbohydrate metabolism, and GI disease pathways. Abundances of six bacterial taxa assayed were
increased in cases. The 23 differential metabolites demonstrated correlations with bacteria that were different between cases and
controls. These findings suggest that metabolic products of bacteria may be responsible for the development of colorectal
adenomas and CRC.
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■ INTRODUCTION
Colorectal cancer (CRC) is the third leading cause of cancer
death in the United States, accounting for almost 9% of all cancer
death in 2011.1 This complex disease is characterized by a series
of pathological stages with benign adenomas as intermediate
precursors. The exact etiology of CRC is still unknown, but
current literature suggests that diets low in fiber and high in red
meat intake are among the significant risk factors for CRC
incidence.2,3 Diet may be responsible directly for CRC risk or
may exert effects through the products of bacterial metabolism
of unabsorbed dietary constituents in the colon. A number of
studies have now linked the gastrointestinal (GI) microbiome
to CRC development, although the mechanisms by which this
occurs are not yet clear.3−5
The microbiome, which refers to the microorganisms that
inhabit the human body in both normal and abnormal
physiological states, has been important in our recent under-
standing of many disease processes. It has been implicated in
the development of a number of conditions including skin
diseases,6 inflammatory bowel disease (IBD),7,8 obesity,9−11 and
CRC.3,12−14 The GI microbiota are responsible for the
cometabolism of many food products. Byproducts of host
dietary metabolism as well as these products of bacterial
metabolism contribute to the GI metabolome. Bacterial
fermentation of proteins and amino acids occurs primarily in
the distal colon, and several metabolites of this fermentation
process are thought to have negative effects on colon health
and could potentially lead to disease.15 Bacterial metabolism of
carbohydrates can generate compounds such as short-chain fatty
acids that are potentially beneficial.15 Additionally, metabolites
from host cells can also preferentially select for the growth of
certain bacteria in the GI tract.16
Metabolomics is defined as “the science of examining the
unique chemical fingerprint of a cell, tissue, or organ by
measuring the global variation of metabolites present.”17 The
group of metabolites produced during metabolic processes is
known as the metabolome.17 The metabolome is the ultimate
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physiological response of biological systems to genetic or
environmental changes and as such has generated much interest
as a tool for better understanding these physiological responses
in many disease states.18 As early as 1989, experiments in the
colon adenocarcinoma cell line HT29 demonstrated that
metabolic changes occur in CRC.19 More recently, alterations
in the metabolome have been reported in IBD, fulminant type 1
diabetes (FT1DM), hepatomas, and breast tumors.18,20,21 A few
studies have found changes in metabolites in the colon tissue,
urine, serum, and feces of patients with CRC and animal models
of CRC.21−28 Results from studies on the metabolome and CRC
have varied in tissue type assayed, methods for metabolome
detection, and identity of detected metabolites. Although many
perturbed metabolic pathways, such as glucose and fatty acid
metabolism, have been demonstrated by these studies, further
investigation is needed to better understand the metabolome in
CRC. To our knowledge, there have been no studies that have
evaluated the metabolome in relation to gut bacterial dysbiosis
and human colorectal neoplasia.
The relationship between the microbiome and the metab-
olome is just starting to be understood. We hypothesize that an
altered metabolome caused by microbial dysbiosis contributes
to the development of adenomas and CRC. In the current study,
we characterized the rectal mucosal metabolome in subjects
with and without colorectal adenomas. We also assessed the
correlation between the metabolome and GI microbiome in
these subjects. Investigating the concurrent changes in meta-
bolites and the microbiome provides an important opportunity
to begin to understand their physiological interplay and their role
in colorectal adenomas and cancer.
■ EXPERIMENTAL SECTION
Participants and Collection of Rectal Biopsies
Participants (15 subjects with adenomas and 15 adenoma-free
control subjects) were randomly selected from persons age
30 years or older who underwent screening colonoscopy at the
University of North Carolina Hospitals (Chapel Hill, NC). The
methods of this study have been previously described.3 Eligible
subjects gave written informed consent to provide colorectal
biopsies and a phone interview that included questions about
diet and lifestyle. Information on diet was obtained from a
comprehensive, validated, quantitative food-frequency question-
naire developed at the National Cancer Institute. At the time of
the colonoscopy, the research assistant measured waist−hip ratio
(WHR) and weight and height to determine body mass index
(BMI). Inclusion criteria included visualization of the entire
colon and a good preparation to avoid the misclassification of
cases and controls. Exclusion criteria included colitis (either
ulcerative, Crohn’s, radiation or infectious colitis, chronic
inflammatory illnesses), previous colonic or small bowel
resection, previous colon adenomas or colon cancer, sigmoido-
scopy or incomplete colonoscopies, familial polyposis syndrome,
or antibiotic use within the last 3 months.
Specimen collection was carried out as previously described.3,5
In brief, normal rectal mucosal biopsies were collected for
each patient at approximately 10−12 cm from the anal verge,
immediately after inserting the scope. The biopsies from all
subjects were collected from normal rectal mucosa and not
adenomas as the adenomas were used for clinical diagnosis.
For subjects that had adenomas, the location, size, and number of
adenomas were recorded during the procedure. The normal
rectal mucosal biopsies were rinsed in sterile phosphate-buffered
saline to reduce contamination with fecal matter and snap-frozen
in liquid nitrogen on site and transferred to −80 °C until
processing for DNA extraction and metabolome analyses. A
pathologist examined all pathologic specimens to confirm
adenoma case status and recorded the number of polyps, size,
location, and histology. Subjects with confirmed adenomatous
polyps were classified as cases and those without adenomas as
controls. This study was approved by the Institutional Review
Board at the UNC School of Medicine (study no. 05-3138).
Metabolomics
The methods for metabolome characterization in tissue biopsies
are similar to those performed by Liao et al.29 A ∼10 mg colon
biopsy was used for a two-step metabolite extraction with
4-chlorophenylalanine (used as an internal standard). First, the
samples were extracted with 200 μL of methanol: chloroform
(3:1) with homogenization in 1.5 mL of screw cap tubes for
3 min using 1 mm inner diameter beads in a Bullet Blender
(Next Advance, USA). After centrifugation, the supernatant
was transferred to a new tube. The remainder was extracted with
200 μL of methanol, and the supernatant was combined with the
first step extraction supernatant.
The samples were first analyzed by liquid chromatography
time-of-flight mass spectrometry (LC−TOFMS, Agilent
Corporation, Santa Clara, CA). After LC−TOFMS analysis,
the samples were derivatized with N,O-bis(trimethylsilyl)-
trifluoroacetamide (BSTFA) and analyzed by gas chromatog-
raphy time-of-flight mass spectrometry (GC−TOFMS, Leco
Corporation, St. Joseph, MI). The metabolic profiling pro-
cedures were performed according to previous publications.23,30
Two samples failed in the derivatization process in GC−TOFMS
analysis and were excluded from the data set. Metabolite
annotation was performed by comparing the mass spectrum and
retention time to our in-house reference library (University of
Hawaii Cancer Center, Honolulu, HI) and NIST library (NIST,
Gaithersburg, MD) for GC−TOFMS generated data or Human
Metabolome Database (HMDB, http://www.hmdb.ca/) for
LC−TOFMS generated data.
DNA Isolation
Bacterial genomic DNA was extracted as previously reported.4
In brief, two rectal biopsies per subject (10−20 mg per biopsy)
were processed with bead-beating and homogenization in
lysozyme (30 mg/mL; Sigma, St. Louis, MO) followed by extrac-
tion with the Qiagen DNeasy Blood & Tissue kit (Qiagen,
Valencia, CA cat. no. 69581) as per manufacturer’s protocol.
The DNA samples were stored in aliquots at −20 °C.
DNA from the positive control strains Lactobacillus sp.,
Escherichia coli, Bif idobacterium sp., Clostridium sp., Bacteroides
sp., and Eubacteria (universal) was isolated using TheUltraClean
Microbial DNA isolation kit (MO BIO Laboratories, Carlsbad,
CA, cat no. 12224-50) per manufacturer’s instructions. Positive
control bacterial strains were cultured as previously described.31
Quantitative Real-Time PCR (qPCR)
In recent publications, we reported that the mucosal microbiome
is altered in adenoma subjects compared with controls.3−5
The abundances of some specific bacteria identified in these
previous studies, including Lactobacillus sp., Escherichia coli,
Bif idobacterium sp., Clostridium sp., Bacteroides sp., and
Eubacteria (universal), were evaluated by qPCR with primers
that amplify 16S rDNA (Supplemental Table 1 in the Supporting
Information). Each qPCR was carried out in duplicate in a final
volume of 25 μL and contained 1× Fast-SYBRGreenMaster Mix
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(Applied Biosystems, Grand Island, NY, cat no. 4385612),
0.5 μM of each primer, and 50 ng of purified DNA. PCR
conditions were as follows: 10 min at 95 °C, followed by
40 cycles of 95 °C for 15 s, 20 s at the appropriate annealing
temperature (Supplemental Table 1 in the Supporting
Information), and 72 °C for 1 min. Melting curve analysis of
the PCR products was conducted following each assay to confirm
that the fluorescence signal originated from specific PCR pro-
ducts and not fromprimer-dimers or other artifacts. PCR reactions
were carried out on a Biorad CFX 384 Real-Time System with a
C1000 Touch Thermal Cycler (Biorad, Hercules, CA).
To generate a standard curve, we amplified the target 16S rRNA
from a positive control strain by PCR. Each resulting amplicon was
inserted into a vector using the TOPOTACloningKit (Invitrogen,
Grand Island, NY, cat. no. K4500-01) as per manufacturer’s
instructions, and the number of copies was calculated as previously
reported to generate the standard curve.5 The copy number of each
specific bacteria in biopsy samples was calculated as previously
reported using the appropriate standard curve.5
Statistical Analyses
Analysis of the metabolome data was conducted using SIMCA-P
software (Umetrics, Umea, Sweden). Principle component
analysis (PCA) was first performed to check the outliers and
the separation tendency. A further supervised partial least-
squares-discriminant analysis (PLS-DA) was performed. Differ-
ential metabolites were selected from the PLS-DA model using a
combination of variable importance in the projection (VIP) value
>1 and p value (Student’s t test) < 0.1. The VIP estimates the
importance of each variable in the PLS-DA model; variables with
a VIP score >1 are important in the model. A p value of <0.1 was
chosen because it allows a broader interrogation of the data that
can be investigated further in the future. Wilcoxon tests were
used to compare the differential metabolites while adjusting for
multiple testing.32 Unpaired, two-tailed Student’s t test with
Welch’s correction for unequal variances was used to compare
qPCR data between cases and controls. Unconditional logistic
regression models and Spearman’s correlation were used to
assess the association between metabolites and specific bacteria
in adenoma cases and nonadenoma controls using JMP (SAS,
Cary, NC). We examined the association between metabolites,
bacteria, and adenomas while adjusting for potential covariates
such as BMI, WHR, age, and gender.
The Ingenuity Pathway Analysis (IPA) Program (Ingenuity
Systems, Qiagen, Redwood City, CA) was used for functional
and pathway analysis to sort dysregulated metabolites into
biologically relevant functional pathways.
■ RESULTS
Characteristics of study subjects are shown in Table 1. Adenoma
cases and nonadenoma controls showed comparable general
characteristics. Several risk factors evaluated showed no
significant differences between cases and controls; however,
cases trended toward having elevated caloric intake, dietary fat,
and dietary fiber consumption compared with controls. Among
cases with adenomas, 60% had small adenomas (1−5 mm),
33.33% had medium adenomas (6−10 mm), and 6.67% had
large adenomas (>10 mm). The mean number of adenomas
per subject was 2 (range 1−7), while the location of adenomas
was 46.67% distal (splenic flexure, descending colon, sigmoid,
rectosigmoid, and rectum), 33.33% proximal (cecum, ascending
colon, hepatic flexure and transverse colon), and 20% both
locations.
Altered Mucosal Biopsy Metabolome in Adenoma Cases
We identified a total of 274 metabolites by GC−TOFMS and
LC−TOFMS (Supplemental Table 2 in the Supporting
Information). PCA was first performed to check the outliers
and the separation tendency (Figure 1A). A further supervised
PLS-DA using two components (R2X = 0.394, R2Ycum = 0.511,
Qcum
2 = 0.132, p value = 0.0079) was performed, resulting in
some separation tendencies between adenoma cases and
nonadenoma controls (Figure 1B). Of the detected metabolites,
23 metabolites were found to be significantly different between
adenoma cases and nonadenoma controls, with most metabolites
having a lower concentration in case subjects (Table 2).
Detected Metabolites Correlate Differentially with Bacteria
between Cases and Controls
We recently reported that the mucosal microbiome is altered in
adenoma subjects compared with controls, with increased
microbial diversity and richness as well as altered abundance of
select bacterial taxa.3−5 The abundances of some specific bacteria
identified in these previous studies were quantified from normal
rectal mucosal biopsies of adenoma cases and nonadenoma
controls (Figure 2). Cases showed a general trend of increased
abundance of bacteria; Bif idobacterium sp. and Eubacteria
abundances were significantly increased in cases compared
with controls (p = 0.0021 and 0.0036, respectively).
We also examined the relationship between the 23 differential
metabolites and specific bacteria taxa in adenoma cases and
nonadenoma controls. The correlation patterns between the
metabolites and specific bacteria differed markedly for cases and
controls (Figure 3). In particular, the direction of correlation
between the metabolites and bacteria are altered between cases
and controls, suggesting that the bacteria and metabolites are
interacting differently depending on adenoma status (Figure 3).
We then evaluated the correlation between specific bacteria and
each metabolite and examined those that were the most highly
correlated with each metabolite. Strikingly, all differential
metabolites except dihydroceramide were most highly correlated
with different bacteria between cases and controls (Supplemental
Table 3 in the Supporting Information). However, while
Table 1. Characteristics of Study Subjects
characteristica case (n = 15)b control (n = 15)b p valuec
age (mean, s.e.) 54.3 ± 1.1 55.0 ± 1.1 0.68
sex (% male) 40 27.7 0.44
body mass index (mean, s.e.) 27.71 ± 1.3 27.4 ± 1.6 0.89
waist−hip ratio (mean, s.e.) 0.90 ± 0.02 0.86 ± 0.02 0.21
calories (mean, s.e.) 2085.7 ± 205.3 1741.3 ± 124.6 0.16
dietary fat (mean, s.e.) 80.5 ± 10.8 63.9 ± 6.6 0.21
dietary fiber (mean, s.e.) 25.2 ± 2.8 21.4 ± 1.6 0.26
as.e. = standard error of the mean. bcases = with adenoma; controls = without adenoma. cp value was calculated from Student’s t test.
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dihydroceramide was most highly correlated with Eubacteria
in both cases and controls, the correlation was inverse for cases
and direct for controls (Supplemental Table 3 in the Supporting
Information).
Differential Metabolites Are Associated with Pathways
Related to Cancer, Gastrointestinal Disease, Inflammation,
and Carbohydrate Metabolism
We performed a supervised pathway analysis with IPA to
analyze the functional pathways most perturbed by the 23
differential metabolites observed for adenoma cases and
nonadenoma controls (Table 2). The resulting pathways were
significantly (p < 0.02) related to cancer, the inflammatory
response, carbohydrate metabolism, and general GI diseases
(Figure 4).
■ DISCUSSION
In the current study, we characterized the metabolome in the
normal rectal mucosa of subjects with and without col-
orectal adenomas. We also assessed the relationship between
the metabolome and specific bacteria taxa in these subjects.
Table 2. Differential Metabolites between Adenoma Cases and Non-Adenoma Controls
rank compound name VIPa p valueb FDR (0.15)c fold changed detectione identificationf
1 galactose 2.45 0.0096 0.0424 −2.81 GC−TOFMS NIST
2 13,14-dihydro-15-keto-PGE2 2.23 0.0198 0.0424 −1.91 LC−ES+ HMDB
3 5-oxoproline 2.21 0.0215 0.0424 −1.56 GC−TOFMS Std
4 2,4-diaminobutyric acid 2.07 0.0319 0.0424 −1.25 LC−ES+ HMDB
5 pentadecanoic acid 1.97 0.0425 0.0424 −1.28 GC−TOFMS NIST
6 5-hydroxyindoleacetic acid 1.96 0.0433 0.0424 −1.98 LC−ES− HMDB
7 phosphoric acid, 2-aminoethanol 1.93 0.0473 0.0424 2.51 GC−TOFMS NIST
8 dihydroceramide 1.92 0.0480 0.0424 −2.05 LC−ES+ HMDB
9 ornithine 1.89 0.0519 0.0424 −2.49 GC−TOFMS Std
10 linoleic acid 1.88 0.0539 0.0424 1.79 LC−ES− HMDB
11 petroselinic acid 1.86 0.0565 0.0424 1.78 LC−ES− HMDB
12 LysoPC (18:2(9Z,12Z)) 1.85 0.0575 0.0424 2.59 LC−ES+ HMDB
13 myo-inositol 1.84 0.0595 0.0424 −1.36 GC−TOFMS NIST
14 diketogulonic acid 1.83 0.0602 0.0424 −8.06 LC−ES− HMDB
15 prostaglandin E2 1.82 0.0615 0.0424 1.54 LC−ES− HMDB
16 methionine 1.76 0.0722 0.0425 −2.37 GC−TOFMS Std
17 2-aminobutyric acid 1.74 0.0756 0.0425 −2.18 GC−TOFMS Std
18 oleamide 1.72 0.0797 0.0425 −1.95 LC−ES+ HMDB
19 glycine 1.69 0.0842 0.0425 −1.41 GC−TOFMS Std
20 maltitol 1.69 0.0849 0.0425 −2.08 GC−TOFMS NIST
21 2-phenylglycine 1.68 0.0862 0.0425 −1.89 LC−ES+ Std
22 2-phenylacetamide 1.66 0.0905 0.0426 −2.66 LC−ES+ HMDB
23 N6-acetyl-L-lysine 1.62 0.0996 0.0448 −1.66 LC−ES+ Std
aVariable importance in the projection (VIP) was obtained from PLS-DA with a threshold of 1. bp value was calculated from Student’s t test with a
threshold of 0.1. cAll metabolites were discriminant (p < 0.05) with an FDR of 15%. dFold change with a value larger than one indicates a relatively
higher concentration in the case samples, while a value less than one means a relatively lower concentration as compared with control samples.
eDetection methods used were liquid chromatography coupled to time-of-flight mass spectrometry with positive or negative electrospray (LC−ES+
and LC−ES−, respectively) or gas chromatography time-of-flight mass spectrometry (GC−TOFMS). fMetabolites were identified by our in-house
library (Std), NIST library (NIST), or HMDB database (HMDB).
Figure 1. (A) PCA scores plot and (B) PLS-DA scores plot of adenoma cases and nonadenoma controls (PLS-DA using two components; R2X = 0.394,
R2Ycum = 0.511, Qcum
2 = 0.132, p value = 0.0079).
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We found that the metabolome was significantly different in
subjects with adenomas compared with nonadenoma control
subjects. Interestingly, the association between metabolites and
bacteria differed depending on adenoma status, suggesting a
potential role for the interaction of the metabolome and
microbiome in the development of CRC. To our knowledge,
this is the first report to directly relate mucosal metabolites with
bacteria in the development of colorectal adenomas and cancer.
Figure 3. Correlation between differential metabolites and bacterial taxa in adenoma cases and nonadenoma controls.
Figure 2. Quantitative real-time PCR of select bacteria from mucosal biopsies of adenoma cases and nonadenoma controls. P values were calculated
from Student’s t test.
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We evaluated the tissue metabolome in normal rectal mucosa
of adenoma cases and nonadenoma controls in the current study
to better understand themetabolic changes in CRC.We detected
274 metabolites by GC−TOFMS and LC−TOFMS, from which
23 metabolites were found to be differentially expressed in
adenoma cases. In this study, we used the PLS-DA model to
select metabolites to investigate and describe interesting
differences between these two groups and their relation to
bacteria. We observed decreased metabolites related to
nucleotide metabolism, such as glycine, and increased levels
of fatty acids, such as linoleic acid, in adenoma cases compared
with controls. Few other studies have reported an altered tissue
metabolome in CRC, primarily decreased tricarboxylic acid
(TCA) cycle metabolites and lipid-derived metabolites in cancer
tissue and increased glycolytic pathways.25,27,28,33−35 While
studies have observed no association between the serum
metabolome and stage of CRC (stages I−IV),23,36 the differences
in metabolism between CRC and adenomas, which are
intermediate precursors, may explain the contradictions between
our observations and others in the literature. Future studies with
larger sample sizes that explore models to discriminate between
cases and controls may provide additional insights.
Pathway analysis of the 23 differential metabolites between
adenoma cases and nonadenoma controls showed that they were
significantly related to inflammation, GI disease, and cancer
pathways. Prostaglandin E2 (PGE2) was a key metabolite in this
pathway analysis that was significantly increased in adenoma
cases in our study. PGE2 is a prostaglandin that is synthesized
from arachidonic acid, an omega-6-fatty acid, by cyclooxygenase
enzymes (COX1 and COX2). PGE2 and COX2 have been
implicated in the development of malignant tumors. PGE2 can
promote tumor extension37 and growth by activating prolifer-
ation, migration, aberrant apoptosis, and angiogenesis.38 Non-
steroidal anti-inflammatory drugs (NSAIDs), which inhibit COX
enzymes, have been shown to reduce the risk of CRC.39 PGE2
has also been linked to cellular proliferation in CRC40,41 and
CRCmetastasis.42 Our observation that PGE2 is increased in the
normal mucosa of patients with adenomas is consistent with
this metabolite’s role in CRC, lending validity to the functional
importance of the metabolites reported in our study. Further-
more, the observed increase in PGE2 highlights the importance
of inflammatory processes early in the development of adenomas
and CRC.
Among the 23 differential metabolites in this study, two
metabolites related to oxidative stress, 5-oxoproline and
diketogulonic acid, were significantly decreased in adenoma
cases compared with nonadenoma controls. 5-Oxoproline is a
byproduct of glutathione synthesis43 and has been proposed as a
biomarker of glutathione status.44 Glutathione is an endoge-
nously synthesized molecule that is a key cellular antioxidant;
when concentrations of glutathione are depleted, cells are
susceptible to DNA damage that can lead to carcinogenesis.44
Glutathione has also been implicated in growth-factor-
mediated chemoresistance of colon cancer cells.45 In other
studies investigating the metabolome, 5-oxoproline was reported
as a metabolite marker in fulminant type 1 diabetes20 and was
dysregulated in the urine of patients with CRC.22 Decreased
levels of 5-oxoproline reported in the current study suggest that
glutathione levels may be decreased in adenoma cases, giving
insight into the potential role that oxidative stress plays in the
development of colorectal adenomas.
Diketogulonic acid, a metabolite of ascorbic acid (vitamin C)
degradation, was also decreased in adenoma cases.46 Like
glutathione, ascorbic acid is an antioxidant that protects cells
against oxidative stress from reactive oxygen species.46 Ascorbic
acid cannot be synthesized by human cells and must be obtained
from the diet and is typically metabolized by bacteria in the GI
tract.46 Intake of ascorbic acid has been disputed as protective
Figure 4. Pathway analysis of 23 differential metabolites with IPA.
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against CRC,47,48 and very little is known about the role of
diketogulonic acid in CRC. In our subjects, there was no dif-
ference in ascorbic acid intake (dietary and supplemental)
between cases and controls (data not shown), yet decreased
levels of diketogulonic acid were observed in cases. This suggests
that ascorbic acid metabolism is altered in the rectal tissue of
subjects with adenomas, which we propose may contribute to
decreased antioxidant capacity of ascorbic acid and increased
oxidative stress. Taken together, these data indicate an important
role for oxidative stress and antioxidant metabolism in the
development of colorectal adenomas.
The interdependence of ascorbic acid metabolism and bacteria
in the GI tract is one example of many ways in which the
microbiome and metabolome interact in health and disease.
Along with vitamin metabolism, fermentation of dietary proteins
and amino acids by bacteria occurs in the GI tract and is a
significant way in which humans break down food. Additionally,
metabolites from host and bacterial cells can preferentially select
for the growth of certain bacteria in the GI tract.16,49 In 2008, Li
et al. published the first article reporting a correlation between
cometabolites and microbes in humans,50 and the production
of certain metabolites by different bacteria has been further
detailed. Since then, Marcobal et al. demonstrated in specifically
reconstituted gnotobiotic mice that bacterial communities
could drive major changes in the host metabolomic profile.51
Many studies have implicated dysbiosis or dysregulation of
the metabolome in CRC, yet to the authors’ knowledge, none
have directly correlated the microbiome and metabolome to
colorectal adenomas or cancer.
In the current study, we examined the abundance of specific
bacteria taxa observed in our previous studies to investigate the
relationship of the bacteria to differential metabolites. Significant
increases in the abundances of Bif idobacterium sp. and Eubacteria
(universal) were observed, while the abundances of Escherichia
coli, Clostridium sp., and Bacteroides sp. were also increased but
the results did not reach statistical significance. These findings
are generally consistent with our prior reports.3−5 However, our
observation that Bif idobacterium sp. were more abundant in the
tissue of patients with colorectal adenomas was surprising.
Bif idobacterium is a genus of lactic-acid-producing bacteria that is
generally viewed as probiotic, yet the relationship between
Bif idobacterium sp. and CRC has been inconclusive. Bif idobacte-
rium adolescentis has been demonstrated to inhibit proliferation
of colon cancer cell lines in vitro,52 and some studies have shown
that administration of lactic-acid-producing bacteria is able to
reduce the occurrence of CRC.53 Chen et al. reported lower
levels of Bif idobacterium sp. in tumor tissue compared with
matched normal mucosa of patients with CRC.54 On the other
hand, Bif idobacterium sp. have been reported to be increased in
the tissue of patients with adenomas.3 Furthermore, higher levels
of the lactic-acid bacterial genus Lactobacillus were associated
with increased risk for CRC.13 Reasons for these conflicting
results are unclear, but the relationship between lactic-acid-
producing bacteria and CRC clearly warrants further inves-
tigation to determine the functional results of microbial dysbiosis
in adenoma and cancer pathogenesis.
To assess the physiological implications of the observed
microbial dysbiosis in our studies, we investigated the relation-
ship between specific bacteria and differential metabolites in
adenoma cases and nonadenoma controls. We report correla-
tions that are significantly different based on disease status, which
may suggest that the interplay between bacteria and meta-
bolites is important in the development of CRC. E. coli contains a
specific metabolic pathway for the degradation of ascorbic acid
to diketogulonic acid.46 However, E. coli is actually inversely
correlated with diketogulonic acid in our data. Additionally, the
correlation is quite similar between cases and controls, indicating
that the difference seen in diketogulonic acid between cases
and controls, although not related to E. coli, may involve other
bacteria that we did not measure. Diketogulonic acid is instead
most highly correlated with Eubacteria in the cases (inverse
correlation) and Clostridium sp. in the controls (direct
correlation). The different bacteria as well as different directions
of correlation suggest that these bacteria or others may
contribute to the disparate metabolism of ascorbic acid in
adenoma cases. Additionally, the correlation of many of the 23
differential metabolites with Eubacteria indicates that there are
other bacteria not specifically assayed that are likely playing an
important role in shaping themicrobiome. Furthermore, the host
diet can alter the gut microbiota functionality, which can result in
an altered metabolome.51 Although we controlled for dietary
calories, fiber, and fat intake, other dietary parameters such as red
meat intake could impact the microbiome and metabolome.
Future studies will aim to elucidate the association between the
metabolome and a wider variety of bacteria in a larger subject
cohort.
While the current study contributes novel insights into the role
of metabolites, microbiota, and their interplay in the develop-
ment of adenomas and CRC, there are several considerations we
recognize as important in the interpretation of these results. The
current study used a small cohort from the same geographic
region (North Carolina, USA). It is also important to consider
the sample type assayed and the comparisons made between
samples when interpreting the current study in relation to other
reports in the literature. We assayed normal mucosal biopsies
from patients with and without adenomas in the current
study. Other studies have focused on serum23,36 or urine22,55
from patients with and without CRC or tumor tissue and
matched normal mucosa only from patients with fully developed
CRC.25,28,33−35 We previously reported a field effect for
apoptosis in the normal tissue of patients with adenomas,39
and our current data suggest that there is a similar field effect on
the metabolome. Therefore, the relationships drawn between
cases and controls in the current study are different than those in
other studies that compare tumor tissue to matched normal
tissue without comparison with subjects without disease.
In summary, our findings demonstrate that in addition to
bacterial dysbiosis the mucosal metabolome is altered in subjects
with colorectal adenomas. Differential metabolites were related
to pathways of inflammation, cancer, and GI disease, and they
may play a role in the development of CRC by lessening the
antioxidant capabilities of the gut metabolome. The correlation
between the altered metabolome and microbiota in the normal
rectal mucosal tissue of subjects with colorectal adenomas is an
exciting observation and one that warrants further investigation
to elucidate the specific interactions between microbes and
metabolites. It may allow for a better understanding of the
pathogenesis of CRC and may lead to identification of novel
markers for diagnostics and therapeutics as well as improved
outcomes for patients with CRC.
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